EEC you gave me a bit of a chuckle when I read your post about the lack of fundamentals for RVX. That is the case for most biotechs so what is your point. With your bursts of successive posts one might guess you have been caught offside in your trading. Is this true?

Anybody who has read my posts knows that I have not been a fan of how the business at RVX is handled. Especially, I think that the bandaid financial plan that this company has been on has resulted in a number of desperation financings and, along with some murky trial results, has created  some very large share price swings. Full disclosure, I have along the way up to and including the last 2 weeks been on both sides of this trade to one degree or another. 

The above being said, the post hoc kidney function results has been the biggest factor in keeping me believing that at the end of the day there would be value in this stock. To me Apabetalone is worth billions if BOM repeats the eGFR and ALP results of the post hocs in this longer trial with sicker patients. To me some of the science released during BOM seems to further support the idea that Apabetalone has positive effects on ALP which seems to support this opinion.

*btw someone asked what traders through Goldman were up to; As of right now they have bought back (on Monday) 150,000 of the 310,200 shares that they sold since Sept 16.